October 31, 2013-The Economic Times: Patent office rejects BDR Pharma's compulsory licensing application

August 6, 2013:
Kractivism: Press Release- Campaign for Affordable Trastuzumab (links to kractivist.org)

August 5, 2013 -
Bio World: China Revokes Viread Patent; Pricing Was at Issue (links to bioworld.com)

May 30, 2013- The Jakarta Globe: Future Hepatitis C Blockbusters May Spawn Compulsory Generics (links to thejakartaglobe.com)

March 18, 2013-
ACTION! Essential Inventions issues request for non-voluntary authorization to use patents under Article 14 of Greece patent law (links to essentialinventions.org)

March 17, 2013-Financial Times: Athens urged to import generic drugs (links to ft.com)

December, 2012
Secondary Patenting: A Threat to Affordable Generic Patenting by I-MAK

November 2, 2012- Nature: NIH asked to grant open license on HIV drug (links to blogs.nature.com)

Compulsory Licenses and Right to Health Litigation


Compulsory Licensing

Crucial right of countries for expanding access to medicines

Countries may exercise their right to issue compulsory licenses to expand access to medicines that are still protected by patents. A compulsory license is a special mechanism that authorizes a government to introduce generic competition for a patented product in exchange for royalty payments to the patent holder. Various countries have issued compulsory licenses on to expand patient access to medicines, ranging from HIV to cancer treatments. Unfortunately, due to various international and domestic pressures, this right is under-utilized by countries whose citizens would benefit.

Litigating the right to health

Human rights law and its relationship to intellectual property protection and access

More than 100 countries have incorporated a right to health into their constitutions, and 160 have acceded to this right through their international treaty obligations. And, in the last fifteen years, domestic courts have gone far to safeguard this right: courts have not only granted plaintiffs access to specific medications, but also commanded governments to make particular medications available to all citizens. More recently, domestic courts have also displayed a growing willingness to use human rights laws to reinterpret and even strike down IP laws that impede access to medications.

Kaletra Campaign

A worldwide campaign to expand access to a vital HIV treatment

On November 10, 2011, public health groups in a dozen countries launched a global campaign to challenge Abbott Laboratories’ monopolistic hold on Kaletra (lopinavir+ritonavir), a critical HIV/AIDS medicine. The goal was to spur competition by generic drugmakers and thereby lower the medicine’s price, as well as to free up its components for new and improved combination treatments. The campaign comprises an unprecedented global effort to fight Big Pharma’s political power and improve access to lifesaving medicines.

About the Kaletra Campaign

Information on Access Actions by Country


"Acting in concert around the world, we will fight pharmaceutical monopoly abuses".--Luz Marina Umbasia, attorney for Colombian treatment groups
 
"We are launching competition campaigns in many countries so we can work together for access"--Sindi Putri, ITPC Indonesia
 
 

Country Spotlight: Vietnam

Access Story Spotlight

Indonesia licenses 7 HIV/AIDS and hepatitis B medicines in an unprecedented move that has extraordinary life-saving potential. Find government order and details on Indonesia's HIV/AIDS response here.
  "I wish the drug company would lower the price, as I know that the number of people taking Kaletra is growing higher and higher – and there are many more who can’t afford the treatment they need." --Naza of Malaysia's PT Foundation 
   

Back to Public Citizen Global Access to Medicines Home Page

Copyright © 2014 Public Citizen. Some rights reserved. Non-commercial use of text and images in which Public Citizen holds the copyright is permitted, with attribution, under the terms and conditions of a Creative Commons License. This Web site is shared by Public Citizen Inc. and Public Citizen Foundation. Learn More about the distinction between these two components of Public Citizen.


Public Citizen, Inc. and Public Citizen Foundation

 

Together, two separate corporate entities called Public Citizen, Inc. and Public Citizen Foundation, Inc., form Public Citizen. Both entities are part of the same overall organization, and this Web site refers to the two organizations collectively as Public Citizen.

Although the work of the two components overlaps, some activities are done by one component and not the other. The primary distinction is with respect to lobbying activity. Public Citizen, Inc., an IRS § 501(c)(4) entity, lobbies Congress to advance Public Citizen’s mission of protecting public health and safety, advancing government transparency, and urging corporate accountability. Public Citizen Foundation, however, is an IRS § 501(c)(3) organization. Accordingly, its ability to engage in lobbying is limited by federal law, but it may receive donations that are tax-deductible by the contributor. Public Citizen Inc. does most of the lobbying activity discussed on the Public Citizen Web site. Public Citizen Foundation performs most of the litigation and education activities discussed on the Web site.

You may make a contribution to Public Citizen, Inc., Public Citizen Foundation, or both. Contributions to both organizations are used to support our public interest work. However, each Public Citizen component will use only the funds contributed directly to it to carry out the activities it conducts as part of Public Citizen’s mission. Only gifts to the Foundation are tax-deductible. Individuals who want to join Public Citizen should make a contribution to Public Citizen, Inc., which will not be tax deductible.

 

To become a member of Public Citizen, click here.
To become a member and make an additional tax-deductible donation to Public Citizen Foundation, click here.